First in new biologics class to treat psoriasis

The first in a new class of biologic medicine that acts to interrupt the inflammatory cycle and help clear the skin of patients with moderate-to-severe psoriasis has been added to the PBS from September 1, 2015. The PBS listing of Cosentyx – the first interleukin-17A inhibitor – for patients with severe chronic plaque psoriasis refractory